help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szepeshazi, K.
Right arrow Articles by Schally, A. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szepeshazi, K.
Right arrow Articles by Schally, A. V.

American Journal of Pathology, Vol 138, 1273-1277, Copyright © 1991 by American Society for Investigative Pathology

REGULAR ARTICLES

Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone- releasing hormone

K Szepeshazi, E Korkut and AV Schally
Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana 70146.

The argyrophilic staining of the nucleolar organizer region (AgNOR) in cells of Dunning R3327 rat prostate tumors was studied and the effect of hormonal treatments on their appearance was analyzed. The nuclei of the control tumor cells contained 4.1 +/- 0.17 AgNOR granules. Treatment of rats for 8 weeks with luteinizing hormone-releasing hormone (LH-RH) agonist (D-Trp-6-LH-RH) and antagonist SB-75 induced a marked inhibition of tumor growth and decreased significantly (P less than 0.01) the number of Ag-NORs in the tumors to 2.89 +/- 0.10 AgNOR granules/cell in the group given the agonist and to 2.82 +/- 0.10 after therapy with the highest dose of the antagonist. A reduced AgNOR number (3.14 +/- 0.16) also was found after 3 days of treatment with SB-75 (P less than 0.05), but the AgNORs returned to near control values 1 week after the short-term therapy, showing the reversibility of these changes. These results suggest that the AgNOR method, which was widely tested on human tumors in the past few years, can be a valuable technique in experimental tumor pathology and useful in the evaluation of the effects of various treatments.


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
A. M. Bajo, A. V. Schally, M. Krupa, F. Hebert, K. Groot, and K. Szepeshazi
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes
PNAS, March 19, 2002; 99(6): 3836 - 3841.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Plonowski, A. V. Schally, A. Nagy, B. Sun, and K. Szepeshazi
Inhibition of PC-3 Human Androgen-independent Prostate Cancer and Its Metastases by Cytotoxic Somatostatin Analogue AN-238
Cancer Res., April 1, 1999; 59(8): 1947 - 1953.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Society for Investigative Pathology.